LC-MS-Based Lipidomic Analysis of Serum Samples from Patients with Type 2 Diabetes Mellitus (T2DM)

Abstract

Background. With the development of social economy, type 2 diabetes mellitus (T2DM) is becoming a severe health problem globally. Methods. To systematically understand the lipid metabolism in T2DM, we applied untargeted lipidomics to the serum of T2DM patients and control group using ultrahigh-performance liquid chromatography (UHPLC) coupled with high-resolution mass spectrometry (MS). Results. Over two thousand molecular features were detected by our approach, of which 222 lipid species in positive ion mode and 145 species in negative were reliably identified based on precise molecular weights and MS/MS patterns. Multivariate analysis was adopted to differentiate T2DM patients and the control group using principal component analysis (PCA) and orthogonal partial least squares discrimination analysis (OPLS-DA). The dysregulated lipid species were found and their significance in pathophysiology was discussed. Correlation analysis of selected lipids and important clinical variables was performed and addressed. Conclusions. This study unveils several new lipids and pathways considerably involved in T2DM and provides novel insights into understanding the pathogenesis underlying T2DM.

Chewing the fat: How lipidomics is changing our understanding of human health and disease in 2022

“…Cancer is the second largest cause of death worldwide with an overall incidence rate of 20.2% over a human lifetime 164 . It has been shown that lipid metabolism in cells is drastically elevated during the different stages of cancer development 165–167 . Increased lipids are needed for plasma membrane synthesis and energy production, but also influence cell membrane compositions to favour metastasis and trigger signalling events within cancer cells.…”

“…Due to the elevated risk of mortality with these diseases, there is a need for strategies in its identification, prevention, and treatment within healthcare. In 2022, as evidenced in Figure 5, the bulk of research articles focussed on related diseases: CVD, 232–255 diabetes, 166,233,249,250,256–278 liver disease, 51,279–293 MetS 277,294,295 and obesity 277,295–305 …”

“…Bibliometric analyses of clinical lipidomics publications in 2022 using Scopus search terms “lipidomics” AND “clinic*” on 15 th December 2022 …”

“…Bibliometric analyses of clinical lipidomics publications in 2022 according to separation techniques, detectors, and RPLC columns used. 51,60,61,68,77,[155][156][157]166,[212][213][214][215][310][311][312][313][314][322][323][324][325][326][327][328][329][330][331][332][333][334][335] All legends are in order of largest to smallest percentage. *Note: All techniques that represent ≥1.0% of total publications have been reported.…”

“…Bibliometric analyses of clinical lipidomics publications in 2022 using Scopus search terms "lipidomics" AND "clinic*" on 15 th December 2022. 51,60,61,68,77,[155][156][157]166,[212][213][214][215][310][311][312][313][314][322][323][324][325][326][327][328][329][330][331][332][333][334][335] . *Note: All biological sample types with more than 1.0% of total publications have been reported individually with all remainder combined under "Other".…”